Supplemental financial information

3 Months Ended

Mar. 31, 2023

Supplemental financial information

Supplemental financial information

3.           Supplemental financial information

Cash, cash equivalents and restricted cash

Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands).

	As of		As of
	March 31,		December 31,
	2023		2022
Cash and cash equivalents	$	44,573	$	56,205
Short-term restricted cash		179		179
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	44,752	$	56,384

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):

	As of		As of
	March 31,		December 31,
	2023		2022
Prepaid clinical	$	2,048	$	3,828
Prepaid insurance		579		1,109
Prepaid manufacturing costs		—		2,380
Other prepaid expenses and current assets		378		329
Total prepaid expenses and other current assets	$	3,005	$	7,646

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	As of		As of
	March 31,		December 31,
	2023		2022
Employee-related expenses	$	256	$	1,724
Development costs and sponsored research		151		84
Clinical trials		—		184
Other		750		780
Total accrued expenses and other current liabilities	$	1,157	$	2,772